Search
Docetaxel
go.drugbank.com/drugs/DB01248ApprovedInvestigational[L46466] Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.[A259676] … Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer.
Synonyms: N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxolProducts: DOCETAXEL EG, Docetaxel Non-Alcohol FormulaCarvedilol
go.drugbank.com/drugs/DB01136ApprovedInvestigational[A182306] Carvedilol was granted FDA approval on 14 September 1995.[L7889] … [L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the
Categories: Compounds used in a research, industrial, or household settingProducts: CARVEDILOLO EGAbaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[A256778] Abaloparatide is an osteoanabolic agent that stimulates bone formation. … [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis.
Categories: Bone Density Conservation AgentsReslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalPatients often experience persistent or exacerbating symptoms overtime despite conventional first-line therapies available. … In four double-blind, randomized, placebo‑controlled trials in patients with severe asthma on currently available therapies, patients receiving reslizumab had fewer asthma attacks, and a longer time to
Terbinafine
go.drugbank.com/drugs/DB00857ApprovedInvestigationalVet approved[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064] … [L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues.
Synonyms: (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine, (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamineProducts: TERBINAFINA EGCefaclor
go.drugbank.com/drugs/DB00833ApprovedInvestigationalSemisynthetic, broad-spectrum antibiotic derivative of cephalexin.
Products: CEFACLOR EGLixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalIt is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).
Mixtures: Suliqua Pen, Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled penCategories: Drugs Used in DiabetesNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001] … [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]
Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone DiseasesImatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigational[L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] … Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".
Products: IMATINIB EG, GLIVEC® 100 MG COMPRIMIDOS CON CUBIERTA PELICULAR